Listed by the USPTO as JUEDES, AMY E
Tech Center 1600 • Art Units: 1644 1675
This examiner grants 45% of resolved cases
JUEDES, AMY E has 929 resolved cases in tech center 1600 and art unit 1644. The allowance rate is 44.8%, while the interview lift is 41.9%. The profile thus combines an allowance rate below half of resolved cases with a strong positive association between interviews and allowance outcomes, making interview strategy particularly relevant to prosecution planning.
The median time to allowance is 1388 days. The listed companies are The Trustees of the University of Pennsylvania, Sloan-Kettering Institute for Cancer Research, and Iovance Biotherapeutics Inc. The leading firms are FOLEY & LARDNER LLP, Knobbe, Martens, Olson & Bear, LLP, and LEYDIG VOIT & MAYER, LTD. These names provide practical context for applicant and counsel experience reflected in the record.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18587251 | METHODS OF TREATING TAU PATHOLOGIES | Non-Final OA | Genentech, Inc. |
| 18037514 | BOVINE ANTIBODY VARIANTS | Non-Final OA | Zoetis Services LLC |
| 17927072 | ENHANCED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | Final Rejection | Tsinghua University |
| 14437902 | METHOD FOR PREPARATION OF A HIGH CONCENTRATION LIQUID FORMULATION OF AN ANTIBODY | Final Rejection | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18580741 | MCT11 ANTIBODIES TO TREAT T CELL FUNCTIONAL EXHAUSTION AND ENHANCE CANCER IMMUNOTHERAPY | Final Rejection | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18281471 | ENGINEERED IMMUNE CELLS AND USES THEREOF | Final Rejection | The Johns Hopkins University |
| 18021687 | B-CELL BASED IMMUNOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS | Final Rejection | Northwestern University |
| 18559146 | INHIBITORY CHIMERIC ANTIGEN RECEPTOR PREVENTS ON-TARGET OFF-TUMOR EFFECTS OF ADOPTIVE CELL THERAPY | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18263658 | IMPROVED T-CELLS FOR CANCER THERAPY USING AMINO ACID STARVATION PATHWAYS | Non-Final OA | UNIVERSITY HEALTH NETWORK |
| 18625699 | METHODS FOR USING ENRICHED EXOSOMES AS A PLATFORM FOR MONITORING ORGAN STATUS | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17735624 | COMPOSITIONS AND METHODS FOR REGULATING CAR T CELLS | Final Rejection | The Trustees of the University of Pennsylvania |
| 18257814 | IMMUNOGENIC COMPOSITIONS | Non-Final OA | FRED HUTCHINSON CANCER CENTER |
| 18429006 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) WITH TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (TNFRSF) AGONISTS AND THERAPEUTIC COMBINATIONS OF TILS AND TNFRSF AGONISTS | Final Rejection | Iovance Biotherapeutics, Inc. |
| 17415175 | Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof | Final Rejection | Iovance Biotherapeutics, Inc. |
| 18042405 | STEM CELL-LIKE MEMORY T CELLS AND USES THEREOF | Final Rejection | GEORGETOWN UNIVERSITY |
| 18286684 | CHIMERIC CYTOKINE RECEPTORS AND USES THEREOF IN CELLULAR THERAPIES | Final Rejection | Nanjing Legend Biotech Co., Ltd. |
| 18003279 | IMMUNOTHERAPY | Final Rejection | NEOGAP THERAPEUTICS AB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy44.8% of resolved applications examined by Amy E Juedes were allowed (929 resolved cases), compared with 35.8% across Art Unit 1644 over the last five years.
This examiner's interview lift is +41.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Amy E Juedes took 1,388 days on average from filing to allowance.
Amy E Juedes examines applications in Art Unit 1644 in Tech Center 1600 (Biotechnology & Pharmaceuticals).